相似文献
1
Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma.
Oncologist. 2018 Feb;23(2):139-142. doi: 10.1634/theoncologist.2017-0415. Epub 2017 Nov 27.
2
Cancer immunotherapy: A paradigm shift in the treatment of advanced urologic cancers.
Urol Oncol. 2017 Dec;35(12):676-677. doi: 10.1016/j.urolonc.2017.09.023. Epub 2017 Oct 18.
3
Immunotherapy for metastatic urothelial carcinoma: putting the brakes on releasing the brake.
Immunotherapy. 2018 Mar 1;10(6):423-425. doi: 10.2217/imt-2018-0007.
4
Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer.
Immunotherapy. 2017 Sep;9(10):781-784. doi: 10.2217/imt-2017-0073.
5
Biomarkers for immunotherapy in urological cancers.
Curr Opin Urol. 2018 Jan;28(1):25-28. doi: 10.1097/MOU.0000000000000465.
6
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies.
Cancer Treat Rev. 2018 Jul;68:80-85. doi: 10.1016/j.ctrv.2018.06.002. Epub 2018 Jun 5.
7
Update of systemic immunotherapy for advanced urothelial carcinoma.
Urol Oncol. 2017 Dec;35(12):678-686. doi: 10.1016/j.urolonc.2017.09.021. Epub 2017 Oct 25.
8
[Immune checkpoint inhibition in metastatic urothelial carcinoma].
Aktuelle Urol. 2018 Apr;49(2):178-186. doi: 10.1055/a-0581-4395. Epub 2018 Mar 27.
9
Immunotherapy with radiotherapy in urological malignancies.
Curr Opin Urol. 2016 Nov;26(6):514-22. doi: 10.1097/MOU.0000000000000335.
10
Immunotherapy for the Treatment of Urothelial Carcinoma.
J Urol. 2017 Jan;197(1):14-22. doi: 10.1016/j.juro.2016.02.3005. Epub 2016 Jul 25.
引用本文的文献
1
Optimal Management of Upper Tract Urothelial Carcinoma: an Unmet Need.
Curr Treat Options Oncol. 2019 Apr 1;20(5):40. doi: 10.1007/s11864-019-0637-2.
2
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Oncologist. 2019 Apr;24(4):563-569. doi: 10.1634/theoncologist.2018-0084. Epub 2018 Dec 12.
本文引用的文献
1
FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
Oncologist. 2017 Jun;22(6):743-749. doi: 10.1634/theoncologist.2017-0087. Epub 2017 Apr 19.
2
Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Clin Genitourin Cancer. 2017 Feb;15(1):23-30.e2. doi: 10.1016/j.clgc.2016.05.003. Epub 2016 May 27.
3
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.
J Clin Oncol. 2016 May 1;34(13):1500-9. doi: 10.1200/JCO.2015.65.0218. Epub 2016 Feb 29.
4
Cancer statistics, 2016.
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
5
Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer.
Clin Genitourin Cancer. 2014 Apr;12(2):71-3. doi: 10.1016/j.clgc.2013.11.016. Epub 2013 Nov 14.
6
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
J Clin Oncol. 2012 Feb 10;30(5):507-12. doi: 10.1200/JCO.2011.37.7002. Epub 2011 Dec 19.
7
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.
J Clin Oncol. 2012 Jan 10;30(2):191-9. doi: 10.1200/JCO.2011.37.3571. Epub 2011 Dec 12.
8
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.
J Clin Oncol. 2011 Jun 10;29(17):2432-8. doi: 10.1200/JCO.2011.34.8433. Epub 2011 May 9.
9
Accelerated approval of oncology products: the food and drug administration experience.
J Natl Cancer Inst. 2011 Apr 20;103(8):636-44. doi: 10.1093/jnci/djr062. Epub 2011 Mar 21.
10
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.
J Clin Oncol. 2009 Sep 20;27(27):4454-61. doi: 10.1200/JCO.2008.20.5534. Epub 2009 Aug 17.
Zotero 插件